Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell Leukemia, and Mixed Phenotype Acute Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04128501
• Other study ID #: 2019-0353
• Secondary ID: NCI-2019-0667420
• Status: Recruiting
• Phase: Phase 2
• Start date: May 5, 2020
• Est. completion date: December 31, 2026

Study information

• Verified date: April 2024
• Source: M.D. Anderson Cancer Center
• Contact: Betul Oran
• Phone: 713-792-8750
• Email: boran[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.

Description:

PRIMARY OBJECTIVE: I. To determine relapse-free survival after the use of venetoclax in combination with azacitidine given as maintenance therapy or for eradication of minimal residual disease in patients with high risk acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT). SECONDARY OBJECTIVES: I. To determine the safety and toxicity of venetoclax in combination with azacitidine (type, frequency, severity of adverse events [AEs] and relationship of adverse events [AEs] to venetoclax). II. To determine response duration, overall survival. III. To determine incidence of acute and chronic graft versus host disease (GVHD). IV. To perform matched pairs analysis to obtain bias corrected treatment comparisons of venetoclax + azacitidine (vidaza) (V+V) to standard therapy in the acute myeloid leukemia (AML) patients with no evidence of disease (AML D-) subgroup. EXPLORATORY OBJECTIVE: I. To investigate possible relationships between baseline protein and gene expression signatures/mutation profile and BH3 profiling in predicting relapse-free survival time to the combination. This exploratory analysis will be done for the data from the entire study, accounting for the noted biological variables covariates, as well as disease status and whether or not the patient had AML, by fitting a Bayesian time-to-event regression model with RFS the outcome variable. OUTLINE: Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine subcutaneously (SC) on days 1-5 and venetoclax orally (PO) once daily (QD) on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 125
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Participants 18 to 75 years of age.

2. English and non-English speaking patients are eligible.

3. Participants with AML who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow if they had at least one of the following

disease characteristics:

1. Therapy related AML.

2. Cytogenetics and molecular features consistent with adverse risk group by European LeukemiaNet classification for AML (see Appendix A.).

3. Primary induction failure defined as absence of complete remission after two different lines of anti-leukemia therapy following diagnosis.

4. Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT.

5. Presence of active disease defined as bone marrow blast count >5% at the time of HSCT.

6. Participants transplanted beyond first remission.

4. Participants with biphenotypic or bilineage leukemia (including a myeloid component) or mixed phenotype acute leukemia (MPAL) or who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow.

5. Participants with acute lymphoblastic leukemia; B cell or T cell in original, who are in morphological remission after allogeneic stem cell transplantation with PBSCs or bone marrow.

6. The use of reduced intensity regimen with fludarabine/melphalan (100-140 mg/m2) with or without TBI with post-transplant Cytoxan.

7. The use of myeloablative regimens including: sequential busulfan (AUC at or greater than 4000)/fludarabine with post-transplant Cytoxan or total body irradiation (TBI)/etoposide with any graft versus host disease (GVHD) regimen.

8. Participants on clinical trials investigating different conditioning regimens (with the above described backbone) with investigational agents will be allowed to enroll.

9. Participants who are in remission with no detectable minimal residual disease (MRD)

after allogeneic stem cell transplant should have:

1. Adequate engraftment within 14 days prior to starting study drug:

2. Absolute neutrophil count (ANC) >/= 1.0 x 109/L without daily use of myeloid growth factor (G-CSF) for at least 7 days; and,

3. Platelet >/= 30 x 109/L without platelet transfusion within 1 week

4. Be able to start the drug therapy between 42 to 100 days following HSCT.

10. Persistence or reappearance of MRD by flow cytometry or cytogenetic or molecular testing while being in morphological remission after allogeneic stem cell transplantation. a. When MRD is detected by flow cytometry, disease level at or above the sensitivity level of the test will be required.

• MRD level at or above 0.01% for B cell ALL and T cell ALL.
• MRD level at or above 0.1% for AML and mixed phenotype acute leukemia. b. When MRD is detected by cytogenetics, disease level at or above the sensitivity level of the test will be required.
• The limited of detection is about 0.25% for males and 0.44% for females. c. When MRD is detected by molecular testing, disease level at or above the sensitivity level of the test will be required.
• The limited of detection is 0.01%

11. ECOG performance status of 0, 1, or 2.

12. Serum creatinine </=1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min as defined by the Cockcroft-Gault Equation*

13. Serum bilirubin </= 1.5 x upper limit of normal (ULN).

14. Aspartate transaminase (AST) or alanine transaminase (ALT) </= 2.5 x ULN.

15. Alkaline phosphatase </= 2.5 x UL.

16. Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.

17. Negative serum or urine pregnancy test for women with reproductive potential. The only participants who will be exempt from this criterion are postmenopausal women (defined as women who have been amenorrheic for > 12 months) or participants who have been surgically sterilized or otherwise proven sterile.

Exclusion Criteria:

1. Active acute GVHD grade II or higher.

2. Active chronic GVHD that is extensive (see Appendix C.).

3. Uncontrolled GVHD (see Appendix C.).

4. Concurrent use of systemic immune suppressive other than calcineurin inhibitors, sirolimus and steroids

5. Active uncontrolled systemic fungal, bacterial or viral infection.

6. Active bleeding.

7. Symptomatic or uncontrolled arrhythmias.

8. Significant active cardiac disease within the previous 6 months, including:

1. New York Heart Association (NYHA) class III or IV congestive heart failure see Appendix C.). Unstable angina or angina requiring surgical or medical intervention, and/or

2. Myocardial infarction.

9. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).

10. Prior history of malignancies, other than leukemia, unless the subject has been free of the disease for >/= 1 year. However, participants with the following

history/concurrent conditions are allowed:

1. Basal or squamous cell carcinoma of the skin;

2. Carcinoma in situ of the cervix;

3. Carcinoma in situ of the breast;

4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system).

11. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.

Related Conditions & MeSH terms

• Acute Bilineal Leukemia
• Acute Biphenotypic Leukemia
• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Biphenotypic, Acute
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Mixed Phenotype Acute Leukemia
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
• T Acute Lymphoblastic Leukemia
• Therapy-Related Acute Myeloid Leukemia

Intervention

Drug:
• Azacitidine
Given SC
• Venetoclax
Given PO

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse-free survival (RFS) time	Summary statistics for RFS time will be computed for all patients and within each (disease status, disease type) subgroup. RFS time distributions will be estimated within each subgroup using the method of Kaplan and Meier.	From the date of first administration of venetoclax + azacitidine (vidaza) (V+V), assessed up to 60 days after last V+V dose
Secondary	Overall survival (OS) time	Summary statistics for OS time will be computed for all patients and within each (disease status, disease type) subgroup. OS time distributions will be estimated within each subgroup using the method of Kaplan and Meier.	Up to 60 days after last V+V dose
Secondary	Incidence of severe (grade 3 or 4) infection	Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.	Up to 60 days after last V+V dose
Secondary	Graft-versus-host disease	Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.	Up to 60 days after last V+V dose
Secondary	Incidence of other inter-current adverse events during follow up	Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.	Up to 60 days after last V+V dose
Secondary	Non-relapse mortality	Defined as death from any cause, within 90 days from the start of V+V treatment that is not preceded by disease recurrence. Will be summarized, and relevant parameters will be estimated under appropriate Bayesian models.	Within 90 days from the start of V+V treatment

External Links

•   University of Texas MD Anderson Cancer Center Website